STOCK TITAN

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

On September 22, 2022, Xilio Therapeutics (Nasdaq: XLO) announced its participation in a fireside chat at the Guggenheim Nantucket Therapeutics Conference, scheduled for September 29, 2022, at 10:15 a.m. ET. A live webcast will be available on the company’s website, with access under the “Events & Presentations” section. This presentation will be archived for 30 days. Xilio is focused on developing tumor-selective immuno-oncology therapies aimed at improving cancer patient outcomes through its proprietary GPS platform.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effects, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including its clinical-stage programs, XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, as well as its earlier pipeline, including XTX301, a tumor-selective IL-12. For more information, please visit https://xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.).

For Investor Inquiries:
Myles Clouston
Vice President, Investor Relations
investors@xiliotx.com 

For Media Inquiries: 
Julissa Viana
Vice President, Corporate Communications
media@xiliotx.com 


FAQ

What is the date and time of Xilio Therapeutics' fireside chat at the Guggenheim Nantucket Therapeutics Conference?

Xilio Therapeutics' fireside chat is scheduled for September 29, 2022, at 10:15 a.m. ET.

How can I access the live webcast of Xilio Therapeutics' presentation?

You can access the live webcast on Xilio Therapeutics' website under the 'Events & Presentations' section.

Will the webcast of Xilio Therapeutics' presentation be available after the event?

Yes, a replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.

What is the focus of Xilio Therapeutics' research and development?

Xilio Therapeutics focuses on developing tumor-selective immuno-oncology therapies to improve the lives of cancer patients.

What is the stock symbol for Xilio Therapeutics?

The stock symbol for Xilio Therapeutics is XLO.

Xilio Therapeutics, Inc.

NASDAQ:XLO

XLO Rankings

XLO Latest News

XLO Stock Data

38.78M
25.97M
40.92%
33.5%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM